Reputable weight loss injections: what the clinical evidence actually shows

What the licensed trial programmes found — and why 'reputable' starts there

The most rigorous measure of a weight loss injection's credibility is the clinical trial programme that earned it its MHRA licence. For tirzepatide, that was the SURMOUNT programme. SURMOUNT-1 randomised 2,539 adults with obesity across 72 weeks and found average body-weight reductions of around 20–21% at the 15 mg dose, figures NICE cited directly in its appraisal of tirzepatide (TA1026), published in December 2024. In a subsequent head-to-head study, SURMOUNT-5, tirzepatide also produced greater average weight loss than semaglutide 2.4 mg over the same timeframe. For semaglutide, the STEP 1 trial (68 weeks, nearly 1,961 adults) recorded around 15% average body-weight reduction at the 2.4 mg maintenance dose. Semaglutide's MHRA authorisation for weight management predates tirzepatide's, and NICE assessed it separately in TA875.

These are not small studies or industry press releases. They were published in the New England Journal of Medicine and reviewed by independent committees before any UK licensing decision was made. That process is part of what makes these injections reputable in a meaningful sense: the evidence was tested in public, by people whose job it is to push back on it.

It is also worth knowing that both medicines carry a Black Triangle (▼) designation from the MHRA, meaning they are subject to additional post-market monitoring. That is standard for newer medicines, it is a signal of active oversight, not a warning sign.

What makes an injection source reputable, not just the medicine itself

A licensed medicine from an unlicensed source is not a reputable treatment, it is a risk. The MHRA has been explicit about this. Between 2023 and 2025, enforcement operations seized roughly 20 million doses of illegally traded weight loss medicines with a street value of around £45 million, including the first UK site producing counterfeit tirzepatide pens, raided in Northampton in October 2025. Some of those fakes contained insulin. The medicine's name on the label tells you nothing about what is inside if the source is unverified.

The practical check is straightforward. Any UK pharmacy supplying prescription medicines must be registered with the GPhC; you can confirm registration directly at the GPhC pharmacy register. A GPhC-registered pharmacy is accountable to a regulator with real enforcement powers. One that operates without registration (or that supplies a prescription-only medicine without a valid prescription from a qualified prescriber) is operating outside the law, regardless of how its website looks.

For a broader picture of what a legitimate treatment process involves, the guide to weight loss injections covers the steps from consultation to dispatch in plain terms. Red flags to watch for include sellers promising supply without clinical assessment, pricing far below current market rates, and offers of discount codes for prescription medicines, all of which the MHRA has identified as markers of suspect supply chains.

Who these injections are licensed for in the UK

Tirzepatide is licensed for adults with a BMI of 30 or above, or 27 or above with at least one weight-related condition such as high blood pressure, type 2 diabetes, high cholesterol, or obstructive sleep apnoea. Semaglutide carries similar criteria. NICE's recommendation for tirzepatide in NHS settings is more specific (BMI 35 or above with at least one qualifying comorbidity, with thresholds 2.5 kg/m² lower for South Asian, Chinese, Middle Eastern, Black African or African-Caribbean backgrounds) but private licensing eligibility is broader and is assessed on the individual's full clinical picture, not a single number.

Neither injection is licensed for use in under-18s, during pregnancy, while breastfeeding, or in people trying to conceive. Certain medical histories (including medullary thyroid carcinoma, MEN2, and some gastrointestinal conditions) require prescriber review before treatment is appropriate. If you are wondering how these criteria apply to your situation, comparing the two licensed injectables is a good next step, as eligibility and clinical fit differ between them.

People with obstructive sleep apnoea specifically may find the evidence on weight loss injections and sleep apnoea useful context before a consultation. Suitability is always a clinical decision, not a checklist you complete yourself.

Side effects, safety monitoring, and what to watch for

Both injections share a broadly similar side-effect profile, led by gastrointestinal symptoms: nausea, loose stools, constipation, reflux, burping, and occasionally vomiting. These tend to be most noticeable in the first few weeks after starting or after a dose increase, and many people find they ease as the body adjusts. Fatigue and headache are also reported, particularly early on.

Pancreatitis is a less common but serious risk. In January 2026, the MHRA issued a Drug Safety Update specifically highlighting acute pancreatitis across GLP-1 medicines: severe, persistent stomach pain that radiates to the back (with or without vomiting) warrants urgent medical attention, not a wait-and-see approach. You can report any suspected side effect, and any suspect seller, through the MHRA Yellow Card scheme.

Injection-site reactions are common and usually minor; rotating sites (abdomen, thigh, upper arm) helps. Storage matters too: both pens require refrigeration between 2–8°C; the exact room-temperature window for each is set out in the patient information leaflet and is the definitive reference, not any third-party summary.

For more on technique, storage, and what to do if a dose is missed, the overview of injectable weight loss drugs covers the practical side, and the guide to injectable drugs for weight loss explains how these medicines work mechanically. Your prescriber and the patient information leaflet are the right sources for decisions about your own dose schedule.

One practical note: your pen arrives in plain, unbranded packaging via DPD tracked delivery, with a tracking link on your phone, so there is no guessing on the day it is due. Keeping a sharps container at home from the outset makes safe disposal straightforward from the first pen.

If you have questions about cost context before deciding whether to start, the treatment overview sets out what is included in a private prescription route and what varies between providers. Price is not an irrelevant factor, but for a prescription medicine, it is the wrong primary filter. The right one is whether the supply chain is regulated, the prescriber is qualified, and the clinical assessment is real.

Speak to our prescribers if you would like a same-day clinical review of your suitability; if you are still at the stage of understanding your options, our guide to weight loss injectables is a good place to get your bearings before booking. The consultation is free, and a GPhC-registered Independent Prescriber, not an automated system, reads every response before any prescription decision is made.